Sildenafil is primarily indicated for the treatment of erectile dysfunction (ED) in adult men and for pulmonary arterial hypertension (PAH). ED is characterized by the inability to achieve or maintain an erection, while PAH involves high blood pressure in the pulmonary arteries. Sildenafil enhances blood flow to the penis during sexual stimulation by inhibiting phosphodiesterase type 5 (PDE5), which results in vasodilation. Its clinical significance lies in improving sexual function and exercise capacity in PAH patients. In summary, Sildenafil is vital for managing ED and PAH.
Sildenafil selectively inhibits PDE5, leading to increased levels of cyclic GMP (cGMP) and enhanced vasodilation in the corpus cavernosum.























